Portal de Periódicos da CAPES

CHOROIDAL THICKNESS IN DIABETIC RETINOPATHY

2013; Lippincott Williams & Wilkins; Volume: 34; Issue: 6 Linguagem: Inglês

10.1097/iae.0000000000000053

1539-2864

Inês Laíns, João Figueira, Ana Rita Santos, Alda S. Baltar, Miguel Costa, Sandrina Nunes, Cláudia Farinha, Rita Del Pinto, José Henriques, Rufino Silva,

Acute Ischemic Stroke Management

In Brief Purpose: To analyze the effect of anti–vascular endothelial growth factor agents (anti-VEGF) in submacular choroidal thickness (CT) of diabetic retinopathy (DR) patients. Methods: Cross-sectional study, which included 25 DR patients (50 eyes) divided in 2 groups, according to DR stage and previous treatments: nonproliferative DR and diffuse diabetic macular edema in both eyes, submitted to macular laser in both eyes and anti-VEGF injection only in 1 eye (nonproliferative diabetic retinopathy + diabetic macular edema group, n = 11); and proliferative DR in both eyes, treated with panretinal photocoagulation in both eyes and anti-VEGF injection only in 1 eye (proliferative diabetic retinopathy group, n = 14). In the study visit, all patients underwent optical coherence tomography with enhanced depth imaging protocol. Choroidal segmentation was performed manually. The medium CT in central macular area (CCT) and the CT in centrofoveal B-scan were obtained automatically. Results: The 25 eyes treated with anti-VEGF showed a reduction on CCT (P = 0.002) and subfoveal CT (P = 0.004), compared with the fellow eyes treated with laser only. Independent evaluation of PDR group revealed similar results (CCT, P = 0.02; subfoveal CT, P = 0.03). In nonproliferative diabetic retinopathy + diabetic macular edema group, CCT was also significantly thinner in eyes treated with anti-VEGF (P = 0.04). A correlation between the number of injections and a thinner CT was found in this group (P = 0.03) and in the evaluation of all eyes together (P = 0.03). Conclusion: Diabetic eyes treated with anti-VEGF agents have reduced CT. Cross-sectional exploratory study which suggests that diabetic eyes treated with anti–vascular endothelial growth factor intravitreal injections have a reduction on submacular choroidal thickness, compared with fellow eyes treated only with photocoagulation therapy. The number of injections may influence the amount of this reduction.